Takeda's qdenga®▼ (dengue tetravalent vaccine [live, attenuated]) approved in indonesia for use regardless of prior dengue exposure

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced the company's dengue vaccine, qdenga® (dengue tetravalent vaccine [live, attenuated]) (tak-003), was approved by the indonesia national agency for drug and food control, badan pengawas obat dan makanan (bpom), for the prevention of dengue disease caused by any serotype in individuals six years to 45 years of age. the use of qdenga should be in accordance with official recommendations. qdenga is the only
TAK Ratings Summary
TAK Quant Ranking